摘要
目的对选择性环氧化酶-2(COX-2)抑制剂塞来昔布对不同激素受体乳腺癌细胞的放疗增敏作用进行初步探讨。方法取指数生长期的不同激素受体乳腺癌细胞MCF-7和MDA-MB-231,分为对照组、药物组、照射组和实验组(射线+塞来昔布),利用CCK-8实验测定细胞活性,Transwell实验观察细胞侵袭能力变化,细胞克隆形成实验检测放射增敏作用。结果在一定浓度范围内,塞来昔布可抑制两种细胞的活性,且抑制效应呈量效关系,塞来昔布还能抑制细胞侵袭能力。塞来昔布与X射线联用可显著降低两种细胞的存活分数,在2 Gy照射时最为显著。结论塞来昔布对人乳腺癌细胞MCF-7和MDA-MB-231有显著的放射增敏作用,且能抑制两种细胞的侵袭能力,其机制有待进一步研究。
Objective To discuss the radiation sensitizing effect of selective cyclooxygenase-2 （COX-2） inhibitor, Celecoxib in breast cancer cells with different estrogen receptors status. Methods Two cell lines, MCF-7 and MDA- MB-231 in logarithmic phase were divided into four groups： control group, drug group, radiation group and experimental group （radiation plus Celecoxib）. The cell activity was examined by CCK-8 test. The invastion ability of the cells was analyzed by Transwell test. And the radiation sensitizing effect was detected by clone formation experiment. Re- suits Celecoxib could inhibit the activity of both cell lines and in a dose dependent manner. Celecoxib alone could inhibit the invasion ability of both cell lines as well. Guinness formula showed, after pretreated by 20 μmol/L Celecoxib for 24 hours, both cell lines showed maximum radiation sensitizing effect at 2 Gy dose point. Conclusion Celecoxib can increase the radiation sensitivity of MCF-7 and MDA-MB-231, and inhibit the invasion ability of both cell lines as well. The mechanism should be further investigated.
出处
《中国医药导报》
CAS
2013年第11期80-82,共3页
China Medical Herald
基金
上海市闵行区自然科学研究课题基金资助项目(编号2009MHZ027)
关键词
塞来昔布
乳腺癌细胞
放射治疗
雌激素受体
Celecoxib
Breast cancer cell
Radiation therapy
Estrogen receptor
